Acetylon Pharmaceuticals recently published the outcomes of its preclinical data concerning the mechanism of action of its selective inhibition based treatment of sickle cell (SC) disease/beta-thalassemia (BT). These findings, “Chemical Inhibition of Histone Deacetylases 1 and 2 Induces Fetal Hemoglobin through Activation of GATA2,” were published in…
News
Recent Posts
- FDA expands approval of sickle cell gene therapy to patients as young as 2
- How to process anxiety when your healthcare team changes
- Curcumin-based gel may ease sickle cell pain, early data suggest
- Reflecting on 5 years of finding my voice through writing
- Transplant outperforms standard care for children with sickle cell